ISU Abxis

이수앱지스 · 086890

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$96M (₩132.5B)

Overview

ISU Abxis develops and supplies biopharmaceutical drugs, medicines derived from living cells rather than chemical synthesis, for use in treating serious diseases.

Its products are supplied to patients and healthcare providers, and the company operates as a standalone entity with no consolidated subsidiaries. It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$41.1M

▼ −5.9% YoY

Operating profit · FY2025

US$1.2M

▼ −87.8% YoY

Net income · FY2025

−US$7.7M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$39.4M(₩54.3B)	US$43.7M(₩60.3B)	US$41.1M(₩56.7B)
Operating profit	US$2.8M(₩3.9B)	US$9.7M(₩13.4B)	US$1.2M(₩1.6B)
Net income	US$2.6M(₩3.6B)	US$10.7M(₩14.7B)	−US$7.7M(−₩10.7B)

Revenue

FY2023US$39.4M
FY2024US$43.7M
FY2025US$41.1M

Operating profit

FY2023US$2.8M
FY2024US$9.7M
FY2025US$1.2M

Net income

FY2023US$2.6M
FY2024US$10.7M
FY2025−US$7.7M

Key ratios (FY2025)

ROE

-9.3%

Debt/Eq

38.8%

Op. margin

2.9%

Net margin

-18.8%

Rev. YoY

▼ −5.9%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?